CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis

NYSE:CRL • US1598641074

175.1 USD
-3.51 (-1.97%)
Last: Mar 3, 2026, 11:22 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

CRL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. CRL has only an average score on both its financial health and profitability. CRL has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • CRL had positive earnings in the past year.
  • In the past year CRL had a positive cash flow from operations.
  • CRL had positive earnings in 4 of the past 5 years.
  • In the past 5 years CRL always reported a positive cash flow from operatings.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • CRL's Return On Assets of -2.02% is fine compared to the rest of the industry. CRL outperforms 61.40% of its industry peers.
  • Looking at the Return On Equity, with a value of -4.56%, CRL is in the better half of the industry, outperforming 61.40% of the companies in the same industry.
  • CRL's Return On Invested Capital of 6.60% is fine compared to the rest of the industry. CRL outperforms 77.19% of its industry peers.
  • CRL had an Average Return On Invested Capital over the past 3 years of 6.85%. This is below the industry average of 11.60%.
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROIC 6.6%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • CRL has a better Operating Margin (12.51%) than 73.68% of its industry peers.
  • In the last couple of years the Operating Margin of CRL has declined.
  • The Gross Margin of CRL (34.98%) is worse than 61.40% of its industry peers.
  • In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
Industry RankSector Rank
OM 12.51%
PM (TTM) N/A
GM 34.98%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for CRL has been reduced compared to 1 year ago.
  • The number of shares outstanding for CRL has been reduced compared to 5 years ago.
  • Compared to 1 year ago, CRL has a worse debt to assets ratio.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 2.45 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.45, CRL is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • CRL has a debt to FCF ratio of 4.13. This is a neutral value as CRL would need 4.13 years to pay back of all of its debts.
  • CRL's Debt to FCF ratio of 4.13 is fine compared to the rest of the industry. CRL outperforms 73.68% of its industry peers.
  • A Debt/Equity ratio of 0.68 indicates that CRL is somewhat dependend on debt financing.
  • CRL has a Debt to Equity ratio of 0.68. This is in the lower half of the industry: CRL underperforms 71.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Altman-Z 2.45
ROIC/WACC0.64
WACC10.38%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.29 indicates that CRL should not have too much problems paying its short term obligations.
  • CRL's Current ratio of 1.29 is on the low side compared to the rest of the industry. CRL is outperformed by 77.19% of its industry peers.
  • CRL has a Quick Ratio of 1.02. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • CRL has a Quick ratio of 1.02. This is in the lower half of the industry: CRL underperforms 77.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.02
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.39%.
  • CRL shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.78% yearly.
  • Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -0.85% in the last year.
  • Measured over the past years, CRL shows a small growth in Revenue. The Revenue has been growing by 6.55% on average per year.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%

3.2 Future

  • Based on estimates for the next years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.70% on average per year.
  • The Revenue is expected to grow by 3.26% on average over the next years.
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.03, the valuation of CRL can be described as rather expensive.
  • Based on the Price/Earnings ratio, CRL is valued cheaply inside the industry as 91.23% of the companies are valued more expensively.
  • CRL is valuated rather cheaply when we compare the Price/Earnings ratio to 27.13, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 15.94, CRL is valued correctly.
  • Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 91.23% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.11. CRL is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 17.03
Fwd PE 15.94
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 94.74% of the companies in the same industry are more expensive than CRL, based on the Enterprise Value to EBITDA ratio.
  • CRL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CRL is cheaper than 87.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.62
EV/EBITDA 11.84
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.48
PEG (5Y)3.56
EPS Next 2Y8.98%
EPS Next 3Y8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CRL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CHARLES RIVER LABORATORIES

NYSE:CRL (3/3/2026, 11:22:37 AM)

175.1

-3.51 (-1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18
Earnings (Next)05-05
Inst Owners107.25%
Inst Owner Change3.99%
Ins Owners0.89%
Ins Owner Change4.42%
Market Cap8.62B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.28 (17.81%)
Short Float %6.07%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)-1.14%
PT rev (3m)6.95%
EPS NQ rev (1m)-20.71%
EPS NQ rev (3m)-21.1%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)1.02%
Revenue NQ rev (1m)-0.99%
Revenue NQ rev (3m)-1.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
Industry RankSector Rank
PE 17.03
Fwd PE 15.94
P/S 2.15
P/FCF 16.62
P/OCF 11.68
P/B 2.72
P/tB 142.73
EV/EBITDA 11.84
EPS(TTM)10.28
EY5.87%
EPS(NY)10.99
Fwd EY6.27%
FCF(TTM)10.53
FCFY6.02%
OCF(TTM)14.99
OCFY8.56%
SpS81.58
BVpS64.3
TBVpS1.23
PEG (NY)2.48
PEG (5Y)3.56
Graham Number121.95
Profitability
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROCE 8.35%
ROIC 6.6%
ROICexc 6.84%
ROICexgc 14.71%
OM 12.51%
PM (TTM) N/A
GM 34.98%
FCFM 12.91%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Debt/EBITDA 2.36
Cap/Depr 54.34%
Cap/Sales 5.46%
Interest Coverage 4.94
Cash Conversion 81.47%
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.02
Altman-Z 2.45
F-Score5
WACC10.38%
ROIC/WACC0.64
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year26.23%
EBIT Next 3Y12.9%
EBIT Next 5Y7.36%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%

CHARLES RIVER LABORATORIES / CRL FAQ

What is the fundamental rating for CRL stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRL.


What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?

ChartMill assigns a valuation rating of 5 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.


How profitable is CHARLES RIVER LABORATORIES (CRL) stock?

CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for CRL stock?

The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 6.87% in the next year.